filmov
tv
Afatinib in Patients With Uncommon EGFR Mutations
Показать описание
Sarah Goldberg, MD, discusses the use of afatinib in patients with lung adenocarcinoma who have a rare mutation in EGFR.
0:04:06
Afatinib in Patients With Uncommon EGFR Mutations
0:03:47
Afatinib Therapy for Uncommon EGFR Alterations in NSCLC
0:08:47
Study of 693 NSCLC patients treated with afatinib
0:17:27
How, when, and where to utilize erlotinib, afatinib, and gefitinib in EGFR positive NSCLC
0:01:35
Afatinib for advanced EGFRm-positive NSCLC
0:06:43
Sequential afatinib and osimertinib in EGFR mutation-positive NSCLC patients: updated results
0:03:30
Osimertinib For Uncommon EGFR Mutations in NSCLC
0:16:22
DEBATE: Drug of choice for exon 19 del EGFR mutant NSCLC - Afatinib
0:04:24
Afatinib treatment in squamous cell lung cancer – Video abstract [ID 104177]
0:06:28
Sequential treatment with afatinib and osimertinib in patients with EGFR mutation-positive NSCLC
0:01:47
Dr. West on FDA Approval of Afatinib in NSCLC With Rare EGFR Mutations
0:03:16
Afatinib in Chinese NSCLC patients – Video abstract ID 136579
0:03:08
Side Effect Management With Afatinib
0:00:58
The Activity of Afatinib in Lung Cancer
0:02:34
Afatinib: Dose Modifications and Adverse Events
0:02:45
Activity of EGFR TKIs in patients with NSCLC with uncommon EGFR mutations
0:08:38
Afatinib Plus Cetuximab in Resistant Non-Small Cell Lung Cancer
0:02:34
GioTag: real world data on first-line afatinib followed by osimertinb
0:20:07
Acquired EGFR resistance: What are the current therapeutic strategies?
0:01:30
Dr. Langer on Afatinib for Advanced Non-Small Cell Lung Cancer
0:03:07
Efficacy and Safety of Afatinib vs Erlotinib and Gefitinib in EGFR+ NSCLC
0:06:36
A New Treatment Option for Uncommon EGFR Mutations (BMIC-023)
0:04:09
Frontline Afatinib in EGFR-Mutant NSCLC
0:00:37
Response to systemic anti-cancer therapy in uncommon EGFR mutations
Комментарии